Study Stopped
It has come to our attention that the site was not necessary for our research project.
Validation of a Molecular Prognostic Test for Eye Melanoma
Validation of a Molecular Test for Predicting Metastasis in Patients With Uveal Melanoma
1 other identifier
observational
N/A
1 country
1
Brief Summary
Up to half of patients with ocular melanoma (also called iris, choroidal or uveal melanoma) develop metastasis. We have found that certain molecular features of the eye tumor can be detected by gene expression profiling and accurately predict which patients will develop metastasis. This molecular test could eventually allow high risk patients to receive preventative therapy to delay or prevent the development of metastasis. The goal of this study is to prospectively validate the predictive accuracy of the gene expression-based molecular test and compare it to monosomy 3, the most common but potentially less accurate molecular marker for metastasis in ocular melanoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started May 2007
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 29, 2006
CompletedFirst Posted
Study publicly available on registry
December 4, 2006
CompletedStudy Start
First participant enrolled
May 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2010
CompletedJune 26, 2018
June 1, 2018
3 years
November 29, 2006
June 21, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Presentation of Primary Tumor to Metastasis
60 months
Interventions
Eligibility Criteria
Patients have uveal melanoma and are being treated wither by enucleation or plaque radiotherapy.
You may qualify if:
- clinical diagnosis of melanoma of the iris, ciliary body and/or choroid
- treatment to include enucleation, radiotherapy or local tumor resection
You may not qualify if:
- evidence of marked tumor necrosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Related Publications (5)
Onken MD, Worley LA, Davila RM, Char DH, Harbour JW. Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. J Mol Diagn. 2006 Nov;8(5):567-73. doi: 10.2353/jmoldx.2006.060077.
PMID: 17065425BACKGROUNDOnken MD, Ehlers JP, Worley LA, Makita J, Yokota Y, Harbour JW. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 2006 May 1;66(9):4602-9. doi: 10.1158/0008-5472.CAN-05-4196.
PMID: 16651410BACKGROUNDOnken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol. 2005 Oct;140(4):748-9. doi: 10.1016/j.ajo.2005.04.024.
PMID: 16226537BACKGROUNDFaulkner-Jones BE, Foster WJ, Harbour JW, Smith ME, Davila RM. Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. Acta Cytol. 2005 May-Jun;49(3):297-308. doi: 10.1159/000326153.
PMID: 15966293BACKGROUNDOnken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004 Oct 15;64(20):7205-9. doi: 10.1158/0008-5472.CAN-04-1750.
PMID: 15492234BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
J. William Harbour, MD
Washington University School of Medicine
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 29, 2006
First Posted
December 4, 2006
Study Start
May 1, 2007
Primary Completion
May 1, 2010
Study Completion
May 1, 2010
Last Updated
June 26, 2018
Record last verified: 2018-06